Document Detail

Update on the medical treatment of stable angina.
MedLine Citation:
PMID:  22044707     Owner:  NLM     Status:  In-Data-Review    
Stable angina is a form of coronary artery disease. Its potential to progress requires the most appropriate treatment in order to reduce the incapacitating effect of an acute angina attack and to avoid long-term cardiovascular events. With or without revascularization, pharmacological treatment is an essential component of this treatment strategy, which also involves lifestyle and diet. Statins and aspirin have been shown to be effective in preventing different aspects of coronary artery disease overall. The efficacy of other classes of treatment has been demonstrated in contexts such as stable angina (including postmyocardial infarction) and heart failure (under specific conditions of dosing) for beta-blockers and in contexts such as heart failure, postinfarction and following revascularization for angiotensin-converting enzyme inhibitors. Along with the oldest classes of treatment, such as nitrates (and related derivatives), beta-blockers and calcium channel blockers, new classes of treatments with entirely (trimetazidine, ivabradine) or partly (nicorandil) different mechanisms of action have now been added. The latest antianginal to obtain marketing authorization, ranolazine, is not yet available in France. The different levels of evidence of the efficacy of these pharmacological products vary greatly and overall are higher for those developed most recently. None is devoid of side effects, which must be taken into account in these patients, many of whom are elderly and polymedicated.
Jean-Louis Gayet; Franck Paganelli; Alain Cohen-Solal
Related Documents :
11447307 - Hemodynamic effects of bosentan in patients with chronic heart failure.
9886707 - Clinical epidemiology of heart failure: public and private health burden.
2441197 - Adaptive processes after myocardial infarction.
17921747 - Current understanding of heart failure with preserved ejection fraction.
1361597 - Lipoprotein(a) and accelerated coronary artery disease in cardiac transplant recipients.
21974927 - Regional contrast agent quantification in a mouse model of myocardial infarction using ...
Publication Detail:
Type:  Journal Article     Date:  2011-10-12
Journal Detail:
Title:  Archives of cardiovascular diseases     Volume:  104     ISSN:  1875-2128     ISO Abbreviation:  Arch Cardiovasc Dis     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-11-02     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101465655     Medline TA:  Arch Cardiovasc Dis     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  536-44     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier Masson SAS. All rights reserved.
28 bis, rue du Commerce, 92700 Colombes, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Characteristics of isolated atrial flutter versus atrial flutter combined with atrial fibrillation.
Next Document:  Police encounters with people with intellectual disability: prevalence, characteristics and challeng...